An observational study in Intestinal Tuberculosis, sponsored by Beijing Chest Hospital, Capital Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by Beijing Chest Hospital, Capital Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Tuberculosis with a site in China — 22 open to participants now, 25 under way, 5 of them phase 3. Tuberculosis · China.
Among the 62 studies in Tuberculosis with a site in China, this one is the 8th largest by planned enrollment of the 15 observational ones that give a count, is one of 5 that started in 2026, is one of 15 observational ones, reaches primary completion later than 15 of the 24 other live ones, and was the 58th registered.
1,173 studies on the registry are indexed under Tuberculosis; 177 are open to participants now.
Browse Tuberculosis studies →22 of the 62 studies in Tuberculosis with a site in China are open now. Recruiting first, the newest first:
Huashan Hospital · Sites in China
Ages 3 mo–18 yrs
Huashan Hospital · Sites in China
Ages 14–80
WestVac Biopharma Co., Ltd. · Sites in China
Ages 14+
Xuelin Yang · Sites in China
Ages 15+ · Healthy volunteers
Chengdu CoenBiotech Co., Ltd · Sites in China
Ages 3+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 13 · Phase 3 10 · Phase 4 6
First in 2004; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 252 across 318 observational studies indexed under Tuberculosis.
Median enrollment 241 across the 47 interventional studies, 500 across the 15 observational. Of the 26 that completed or were terminated, 3 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 62 have an industry lead sponsor. The 10 most frequent:
Beijing Chest Hospital, Capital Medical University is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Beijing Chest Hospital, Capital Medical University has 1 study filed under Tuberculosis — fewer than ten, so there is no comparison to draw.
4 of the studies in Tuberculosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07575061Beijing Chest Hospital, Capital Medical UniversityA 15-year Cohort Study on Risk Factors of Mortality in Patients With Intestinal Tuberculosis | 2026-12-01 |
| NCT07459569China-Japan Friendship HospitalDiagnostic Performance and Safety of Endobronchial Ultrasound-guided Transbronchial Mediastinal Cryobiopsy in Diagnosing Tuberculous Mediastinal Lymphadenitis: a Randomised Controlled Trial | 2027-05 |
| NCT06153069Huashan HospitalAsymptomatic TB With Innovative Modified Short-course Regimens | 2027-11 |
| NCT07893444Huashan HospitalBRIGHT-Child TB: Short-Course Treatment for Non-Severe Pulmonary Tuberculosis in Children | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 62 studies in Tuberculosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study adopts a combined design of retrospective cohort study followed by prospective observational study, which is conducted at Beijing Chest Hospital. The study first collects and analyzes the data of intestinal tuberculosis patients diagnosed and followed up in the hospital from 2011-1 to 2025-12 (a 15-year retrospective period) as the retrospective cohort, aiming to initially identify the risk factors associated with mortality in patients with intestinal tuberculosis. On the basis of the retrospective analysis results, the study will further carry out a prospective observational study, continuously enroll new intestinal tuberculosis patients, follow up their clinical status, treatment response and mortality outcomes for a certain period, and verify and supplement the risk factors identified in the retrospective stage. Clinical data, including demographic characteristics, clinical manifestations, laboratory test results, treatment regimens, and follow-up outcomes (mortality status), will be collected and sorted out in both stages. Univariate and multivariate statistical analyses will be used to screen and verify potential risk factors (such as age, disease severity, comorbidities, and treatment compliance) that affect the mortality of patients with intestinal tuberculosis. The results of this study are expected to provide scientific evidence for optimizing the clinical management, risk assessment, and prognostic improvement of patients with intestinal tuberculosis, and further guide the formulation of targeted prevention and treatment strategies.
The study population consists of patients diagnosed with intestinal tuberculosis, covering both the retrospective and prospective research stages. The Retrospective Intestinal Tuberculosis Cohort includes patients diagnosed with intestinal tuberculosis between January 2011 and December 2025, with complete medical records and follow-up data (including mortality status). The Prospective Intestinal Tuberculosis Cohort includes newly diagnosed intestinal tuberculosis patients who can cooperate with follow-up and provide complete clinical information. The study population is mainly used to analyze the risk factors related to mortality in intestinal tuberculosis patients, so as to provide a scientific basis for optimizing clinical management and improving the prognosis of patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This cohort includes intestinal tuberculosis patients diagnosed and followed up in Beijing Chest Hospital from 2011-01 to 2025-12 (15-year retrospective period). The research data are collected by reviewing historical medical records, mainly used for initial screening of mortality-related risk factors.
Other: Observational
This cohort includes newly diagnosed intestinal tuberculosis patients enrolled continuously after the retrospective stage. The research data are collected through dynamic follow-up of the subjects, mainly used for verifying and supplementing the mortality-related risk factors identified in the retrospective cohort.
Other: Observational
Observational
All-cause mortality in patients with intestinal tuberculosis.
Death of the study subject due to any cause during the study period
Time frame: For the Retrospective Intestinal Tuberculosis Cohort, the time frame is 15 years, from January 2011 to December 2025; for the Prospective Intestinal Tuberculosis Cohort, the time frame is 3 years from the date of the first patient enrollment
Plan to share: Yes — The shared IPD includes de-identified clinical data of research subjects.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available for sharing after the completion of the study
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.
Of 123 non-industry observational studies under Tuberculosis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 11 months is below that.
Counting every sponsor, half of 135 studies reached it within 36 months; a quarter within 21 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Chest Hospital, Capital Medical University